Updated guidance on promotional labeling for biosimilars and interchangeables emphasizes a similar approach


The FDA issued a revised draft guidance on the development of promotional labeling for biosimilars, reference products, and—newly—interchangeable products. But the guidance offers little in the way of advice for sponsors of interchangeable products, except to say that companies shouldn’t imply that their products are better than the competition.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap